Insider Trading Alert - ALXN, SUPN And WLDN Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Friday, June 12, 2015, 76 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $100.00 to $5,841,705.00.

Highlighted Stocks Traded by Insiders:

Alexion Pharmaceuticals (ALXN) - FREE Research Report

Moriarty John B, who is EVP & General Counsel at Alexion Pharmaceuticals, sold 914 shares at $170.00 on June 12, 2015. Following this transaction, the EVP & General Counsel owned 32,428 shares meaning that the stake was reduced by 2.74% with the 914-share transaction.

The shares most recently traded at $170.62, up $0.62, or 0.36% since the insider transaction. Historical insider transactions for Alexion Pharmaceuticals go as follows:

  • 4-Week # shares bought: 500
  • 4-Week # shares sold: 256
  • 12-Week # shares bought: 500
  • 12-Week # shares sold: 10,344
  • 24-Week # shares bought: 500
  • 24-Week # shares sold: 55,337

The average volume for Alexion Pharmaceuticals has been 1.9 million shares per day over the past 30 days. Alexion Pharmaceuticals has a market cap of $33.7 billion and is part of the health care sector and drugs industry. Shares are down 8.79% year-to-date as of the close of trading on Friday.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company has a P/E ratio of 57.8. Currently, there are 15 analysts who rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ALXN - FREE

TheStreet Quant Ratings rates Alexion Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, notable return on equity and expanding profit margins. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Alexion Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you liked this article you might like

Alexion Could Target Sage, Ra Pharma: Analyst

Dow, S&P 500 and Nasdaq at New Records as Promise of Tax Reform Boosts Banks

Stocks Back at Highs as Apple Gains on iPhone 8, iPhone X Release

Tech in Wait-and-See Mode Ahead of Apple Event, Financials Rise on Tax Talk

Stocks Come Off Highs as Apple Wait Counters Boost From Tax Reform Talk